Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

  title={Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy},
  author={Anping Li and Ming Yi and Shuang Qin and Yongping Song and Qian Chu and Kongming Wu},
  journal={Journal of Hematology \& Oncology},
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor mass. Cancer immunotherapy eradicates tumor cells by enhancing multiple steps in cancer-immunity cycle including antigen presentation, T cell priming, activation, and immune killing activity. Immunotherapy has been verified as an effective strategy in multiple cancers, but some problems still exist in actual clinical practice such as frequent primary and adaptive… 

cGAS-STING, an important pathway in cancer immunotherapy

The biological characters, current applications, challenges, and future directions of cGAS-STING in cancer immunotherapy are examined.

Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer

It is demonstrated that when various cancer therapies are combined to treat cancer, it can lead to an anticancer immune synergistic effect by increasing the immune response and reducing side effects.

Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy

The advances made in development of NK cell therapeutics for clinical application are highlighted with evidence supporting their combinatorial application with other immune-oncology approaches to improve outcomes of immunotherapies.

STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer

CGAMP could directly activate NK cells and enhance the sensitivity of pancreatic cancer cells to NK cell cytotoxicity, suggesting that cGAMP may become a potential adjuvant for NK cell therapy.

cGAS-STING signaling in cancer immunity and immunotherapy.

Prospects for combining immune checkpoint blockade with PARP inhibition

It is proposed that PARP inhibitors could enhance the priming and tumor-killing activities of T cell, boost the whole cancer-immunity cycle, and thereby improve the response to immune checkpoint blockade.

Cancer immunotherapy with γδ T cells: many paths ahead of us

Recent developments to enhance the efficacy of γδ T cell-based immunotherapy are discussed, including strategies for in vivo activation and tumor-targeting of δ T cells, the optimization of in vitro expansion protocols, and the development of gene-modified γ Δ T cells.

Development of Small-Molecule STING Activators for Cancer Immunotherapy

The synergistic effect of cGAMP-mediated immunity and efficient anti-cancer effects successfully demonstrated the therapeutic potential of KAS-08 for combination therapy in cancer treatment and validated as an effective STING pathway activator in vitro and in vivo.



The host STING pathway at the interface of cancer and immunity.

Analysis of the biology of this natural immune response has revealed a major role for the stimulator of IFN genes pathway (STING pathway), which senses cytosolic tumor-derived DNA within the cytosol of tumor-infiltrating DCs.

Cancer immunotherapy beyond immune checkpoint inhibitors

This review is to include first-in-human phase I and phase I/II clinical trials intended to allow the identification of those drugs that most likely will continue to develop and possibly join the immunotherapeutic arsenal in a near future.

A STING-Activating Nanovaccine for Cancer Immunotherapy

A minimalist nanovaccine by a simple physical mixture of an antigen with a synthetic polymeric nanoparticle, PC7A NP, which generated a strong cytotoxic T cell response with low systemic cytokine expression is reported, suggesting generation of long-term antitumor memory.

Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

It is suggested that PD-1 pathway blockade may reverse adaptive immune resistance following cyclic dinucleotide treatment, enhancing both local and systemic antitumor immunity.

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

The results show how STING-dependent DNA sensing can enhance tolerogenic states in tumors characterized by low antigenicity and how IDO inhibition can overcome this state by attenuating tumor tolerance.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

The generated PancVAX vaccine generated a neoantigen-targeted vaccine that activated a neoepitope-specific T cell repertoire within the tumor and caused transient tumor regression, and resulted in rejection of tumors upon contralateral rechallenge, suggesting the induction of T cell memory.

STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

Significant contributions of STING to antitumor immunity via enhancement of type I IFN signaling in the tumor microenvironment are demonstrated and a potential use of STing agonists for the development of effective immunotherapy, such as the combination with antigen-specific vaccinations is suggested.